Drug class
Cardiometabolic agent; gamma-butyrobetaine hydroxylase and carnitine-transport modulator
Mechanism of action
Inhibits gamma-butyrobetaine hydroxylase and the OCTN2 carnitine transporter, reducing endogenous L-carnitine availability and limiting mitochondrial uptake and beta-oxidation of long-chain fatty acids. This shifts cellular energy metabolism toward glucose oxidation and may reduce oxygen consumption under ischaemic conditions.
General use cases
- Used in selected countries as an adjunctive cardiometabolic treatment for ischaemic heart disease and related circulatory disorders; it is not approved in the United States and is not a universally authorised standard therapy.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
